INTENSITY THERAPEUTICS, INC. (INTS)
About INTENSITY THERAPEUTICS, INC.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$11.6M
- Total assets
- $14.1M
- Market cap
- $10.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.0M
- Operating income
- -$12.0M
- Income tax
- $0
- Net income
- -$11.6M
- EPS (basic)
- $-8.56
- EPS (diluted)
- $-8.56
Balance sheet
- Total assets
- $14.1M
- Current assets
- $12.7M
- Total liabilities
- $2.2M
- Current liabilities
- $2.1M
- Shareholders’ equity
- $11.9M
Cash flow
- Operating cash flow
- -$9.2M
- Investing cash flow
- -$9.3M
- Financing cash flow
- $18.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $10.2M
- EPS (diluted)
- $-8.56
- Shares outstanding
- 2.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 30, 2023
Intensity Therapeutics, Inc. (INTS) Stock Price
- Reported a net loss of $11.6M.
- Trading 87% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review INTENSITY THERAPEUTICS, INC..
Write a review
News about INTENSITY THERAPEUTICS, INC.
News & sentiment via Polygon.io
Intensity Therapeutics, Inc.: frequently asked questions
Is Intensity Therapeutics, Inc. an American company?
Intensity Therapeutics, Inc. is a US-based company headquartered in Shelton, Connecticut, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Intensity Therapeutics, Inc. headquartered?
Intensity Therapeutics, Inc. is headquartered in Shelton, Connecticut, United States.
Is Intensity Therapeutics, Inc. publicly traded?
Yes — Intensity Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol INTS on the NASDAQ.
What does Intensity Therapeutics, Inc. do?
Intensity Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
